The Biotech Century Revisited: What Rifkin and Ridley Got Right—and Wrong

In August 2000, I reviewed two books on genetics and biotechnology: The Biotech Century by Jeremy Rifkin and Genome: The Autobiography of a Species in 23 Chapters by Matt Ridley.

At the time, the Human Genome Project was nearing completion, CRISPR did not yet exist, and “biotech” still felt like a futuristic industry rather than a daily reality. A quarter century later, we can now evaluate these works not as speculation—but as forecasts.

The result is fascinating: both authors were right in surprisingly deep ways, yet both also missed critical dynamics that define biotechnology today.


1. The Rise of Biotechnology: Rifkin Was Early—but Not Entirely Right

Rifkin predicted that biotechnology would become the dominant economic force of the 21st century.

Verdict: Partially correct.

Biotech is undeniably central today:

  • mRNA vaccines (e.g. COVID-19 response)
  • Gene editing using CRISPR-Cas9
  • Synthetic biology startups
  • Personalized medicine

However, biotech did not replace the digital economy—it merged with it.

The real revolution is bio + information technology, exactly the convergence Rifkin described—but underestimated in structure. Companies today are as much data companies as biology companies.


2. Gene Patents and “Biocapitalism”: Rifkin Was Largely Correct

Rifkin warned about the commodification of life and gene patenting.

Verdict: Largely correct—with an important correction.

In the early 2000s, companies did aggressively patent genes. But in 2013, the U.S. Supreme Court ruled in Association for Molecular Pathology v. Myriad Genetics that naturally occurring human genes cannot be patented.

Still:

  • Synthetic DNA can be patented
  • Biotech platforms and therapies are heavily proprietary
  • The industry remains capital-intensive and monopolistic

Rifkin correctly foresaw economic concentration, but the legal system partially resisted the most extreme version of “owning life.”


3. GMOs and the “Second Genesis”: Overestimated Risks, Underestimated Acceptance

Rifkin feared ecological collapse and widespread harm from genetically modified organisms.

Verdict: Mostly wrong (so far), but not trivial.

Reality:

  • GM crops are now widespread globally
  • No major ecological catastrophe has occurred
  • Increased yields and reduced pesticide use in many cases

However:

  • Monoculture and biodiversity concerns remain valid
  • Corporate control over seeds (e.g. large agribusiness firms) reflects Rifkin’s economic concerns more than his ecological fears

The “Second Genesis” did happen—but quietly and pragmatically, not catastrophically.


4. Eugenics and Genetic Stratification: Not Yet—but Getting Closer

Rifkin predicted a “GenRich vs Naturals” divide.

Verdict: Not yet realized—but increasingly plausible.

We now have:

  • Embryo screening (preimplantation genetic diagnosis)
  • Experimental gene therapies
  • First CRISPR-edited babies (controversially in 2018)

However:

  • Germline editing is still heavily restricted
  • No true “designer babies” at scale

Yet the direction is clear:
Rifkin was early, not wrong.

This remains one of the most important unresolved questions for the 21st century—and highly aligned with transhumanist discourse.


5. Genetic Discrimination: A Real Risk—But Politically Contained

Rifkin warned about discrimination by insurers and employers.

Verdict: Correct in principle, mitigated in practice.

For example:

  • The U.S. passed Genetic Information Nondiscrimination Act (GINA)
  • Similar protections exist in Europe

However:

  • Data privacy concerns persist
  • Direct-to-consumer DNA testing (e.g. 23andMe) creates new risks

The issue did not disappear—it was politically managed, not solved.


6. Biology + Computing: One of Rifkin’s Strongest Insights

Rifkin argued that computing and genetics would converge.

Verdict: Completely correct.

Today:

  • AI models are used in protein folding (e.g. AlphaFold)
  • Genomics is fundamentally a data science field
  • Drug discovery is increasingly computational

This is arguably the core paradigm of modern biotech.


7. DNA Computers: A Miss

Rifkin predicted DNA-based computing as a near-term revolution.

Verdict: Wrong (so far).

DNA computing exists in research, but:

  • It is not commercially relevant
  • Silicon-based computing still dominates

He overestimated hardware disruption while underestimating software/AI dominance.


8. Ridley’s View: More Subtle—and More Durable

Unlike Rifkin, Matt Ridley focused less on prediction and more on interpretation.

Where Ridley Was Right

1. Genes are not deterministic
Modern epigenetics confirms this strongly.

2. Evolution is messy and non-linear
Still the dominant view in evolutionary biology.

3. Genes interact in complex systems
Now foundational to systems biology.


Where Ridley Was Too Optimistic or Simplistic

1. “Genes are not for diseases”
Technically true—but:

  • Genetics plays a major role in disease risk
  • Precision medicine is built on exactly this premise

2. Underestimation of technological acceleration
Ridley described genetics—he did not fully anticipate:

  • CRISPR
  • AI-driven biology
  • Synthetic biology as engineering discipline

9. What Neither Author Fully Saw

The biggest blind spot of both books:

The Platformization of Biology

Biology is no longer just science—it is becoming:

  • Programmable
  • Scalable
  • Platform-driven (like software)

Companies now operate on a model closer to tech platforms than traditional pharma.

This is the true “Biotech Century”—but it looks more like Silicon Valley meets evolution.


Final Assessment

Rifkin

  • Strong on risks, ethics, and political economy
  • Often too alarmist
  • Surprisingly accurate on long-term structural trends

Ridley

  • Strong on biological insight and nuance
  • Less predictive, but more scientifically durable
  • Underestimated the speed of technological change

A Prudentia Perspective

From today’s standpoint, the most important realization is this:

We are no longer merely observing evolution—we are beginning to participate in it.

But not in the crude, dystopian way imagined in 2000.

Instead, it is happening:

  • Gradually
  • Unevenly
  • Through markets, regulation, and incremental innovation

The real question is no longer whether a “Biotech Century” will occur.

It already has.

The question is:

Who will shape it—and according to which values?

Claus D. Volko using ChatGPT 

Comments

Popular posts from this blog

Reprogramming Bacteria for Symbiont Conversion: A Review

Summary of "The Inappropriately Excluded"

A Proof of the CTMU - Sketch